Who is sponsoring NCT02554188?

NCT02554188 is sponsored by University of Southern California.

What drugs are being tested in NCT02554188?

Interventions in NCT02554188: Seasonal influenza (flu) vaccine, Diet.

What condition does NCT02554188 study?

NCT02554188 studies Immunosenescence.

Is NCT02554188 still recruiting?

NCT02554188 is currently withdrawn. Last updated 30 October 2019.

Last reviewed 2019-10-30 · How we verify

NCT02554188

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Fasting-mimicking Diet and Immunosenescence

Withdrawn Phase 2 Last updated 30 October 2019

What this trial tests

Phase 2 trial testing Seasonal influenza (flu) vaccine in Immunosenescence. Withdrawn.

Timeline

1 May 2019

Primary endpoint
1 May 2019

1 May 2019

Quick facts

Lead sponsor	University of Southern California
Phase	Phase 2
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	basic science
Start date	1 May 2019
Primary completion	1 May 2019
Estimated completion	1 May 2019

Drugs / interventions tested

Seasonal influenza (flu) vaccine — full drug profile →
Diet

Conditions studied

Immunosenescence — all drugs for Immunosenescence →

Sponsor

University of Southern California

Who can join

Adults 50 to 75, any sex, with Immunosenescence. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this study is to test a Fasting-Mimicking Diet (FMD) for its efficacy on improving immune response to flu vaccination in an older adult population (50-75 years of age).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Immunosenescence

Currently open trials in the same condition.

NCT07341087 — Skin Inflammation in Perimenopause: A Probiotic Intervention Proof of Concept Trial · NA · recruiting
NCT07239830 — Interferon Reference for Older People - REFIPA Study · NA · recruiting
NCT06907329 — The Impact of Nicotinamide Mononucleotide Sustained-release Tablets on Immunosenescence and Metablism in Middle-aged and · NA · recruiting
NCT05322343 — Biobank and Brain Health in Bordeaux. · recruiting

Other University of Southern California trials

Trials by the same sponsor.

NCT07288463 — Hearing Loss and Genetic Risks for Alzheimer's Disease and Related Dementia · NA · not yet recruiting
NCT05914233 — Non-invasive Ultrasound Retinal Stimulation for Vision Restoration · NA · not yet recruiting
NCT06163664 — Role of ChatGPT in Vestibular Schwannoma Management · NA · withdrawn
NCT07332312 — A Culturally Informed Patient Navigation Program (CFPN) to Reduce Delays Between Diagnosis and Treatment in American Ind · NA · not yet recruiting
NCT07290478 — Encouraging Older Adults and Adults With Serious Illness to Designate a Health Care Proxy · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02554188 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Southern California
Last refreshed: 30 October 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02554188.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing